SCHEMBL3819435

SCHEMBL3819435

CC(c1nc2ccc(C#N)cc2c(=O)n1C)N1CCN(S(=O)(=O)c2ccc(Cl)cc2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ S1PR1 P21453 1/20 0.45
▸ NPSR1 Q6W5P4 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPT P10636 1/20 0.44
▸ GPR6 P46095 3/20 0.43
▸ CNR1 P21554 1/20 0.41
▸ HTT P42858 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ ATM Q13315 1/20 0.41
▸ CCR6 P51684 1/20 0.40
▸ CTDSP1 Q9GZU7 1/20 0.39
▸ GBA1 P04062 3/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ CACNA2D1 P54289 1/20 0.38
▸ GAA P10253 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3823767 0.92 GPR6 (0.47) MAPTGPR6HTTLMNAMAPK1
SCHEMBL15457168 0.92 GBA1 (0.43) KMT2AMAPTGPR6HTTUSP2
SCHEMBL3820600 0.90 CFTR (0.46) KMT2AHTTLMNATSHRSMN1; SMN2
SCHEMBL3825309 0.87 ATM (0.44) S1PR1NPSR1KMT2AMAPTHTT
SCHEMBL13723945 0.86 ATM (0.43) NPSR1KMT2AMAPTHTTUSP2
SCHEMBL3821683 0.86 GBA1 (0.44) NPSR1KMT2AMAPTHTTUSP2
SCHEMBL15457257 0.85 GBA1 (0.52) NPSR1KMT2AMAPTHTTUSP2
SCHEMBL15457091 0.85 LMNA (0.47) NPSR1KMT2AHTTUSP2LMNA
SCHEMBL15457123 0.85 HTT (0.45) NPSR1HTTUSP2LMNATSHR
SCHEMBL15457180 0.85 S1PR1 (0.46) S1PR1NPSR1KMT2ACNR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
US-8642609-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-02-04 — — US disclosed
EP-1646615-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2009-08-26 — — EP disclosed
EP-1646615-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS Vertex Pharmaceuticals Incorporated (US) 2006-04-19 — — EP disclosed
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2005-03-17 — — US disclosed
WO-2004111014-A1 PYRIMIDINE DERIVATIVES AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2004-12-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059687-A1 Modulators of ATP-Binding Cassette transporters CFTR, ABCB1, ABCC2 S1PR1 2071/4885NPSR1 3650/4885KMT2A 4344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback